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2390Objectives: The effectiveness of the routine retrosternal placement of a gentamicin-impregnated collagen
sponge (GICS) implant before sternotomy closure is currently a matter of some controversy. We aimed to
develop a scoring system to guide decision making for the use of GICS to prevent deep sternal wound infection.
Methods: Fast backward elimination on predictors, including GICS, was performed using the Lawless and Sin-
ghal method. The scoring system was reported as a partial nomogram that can be used to manually obtain pre-
dicted individual risk of deep sternal wound infection from the regression model. Bootstrapping validation of the
regression models was performed.
Results: The final populations consisted of 8750 adult patients undergoing cardiac surgery through full sternot-
omy during the study period. A total of 329 patients (3.8%) received GICS implant. The overall incidence of
deep sternal wound infection was lower among patients who received GICS implant (0.6%) than patients
who did not (2.01%) (P ¼ .02). A nomogram to predict the individual risk for deep sternal wound infection
was developed that included the use of GICS. Bootstrapping validation confirmed a good discriminative power
of the models.
Conclusions: The scoring system provides an impartial assessment of the decision-making process for clini-
cians to establish if GICS implant is effective in reducing the risk for deep sternal wound infection in individual
patients undergoing cardiac surgery through full sternotomy. (J Thorac Cardiovasc Surg 2014;148:2390-6)Supplemental material is available online.
Median sternotomy is the method of first choice in most
cardiac surgical interventions. Postoperative sternal wound
infections are reported to occur with an incidence of
approximately 0.5% to 8% following median sternotomy.1
Deep sternal wound infections (DSWIs) are particularly
devastating because they are associated with high mortality
rates of 14% to 47%.2
Gentamicin-impregnated collagen sponge (GICS) im-
plants were developed to provide high local antibiotic con-
centrations in wounds thus limiting postoperative bacterial
growth and preventing systemic adverse events (mainly
nephrotoxicity).3 GICS implants have been advocated toe Department of Cardiac Surgery, Harefield Hospital, London, United
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The Journal of Thoracic and Cardiovascular Surreduce the risk of DSWI after cardiac surgical procedures
through sternotomy.4,5 However, the effectiveness of the
routine retrosternal placement of a GICS implant before
sternotomy closure is currently a matter of some
controversy6 and the upfront cost of the routine implant
constitutes a barrier to their widespread implementation.4
On the other hand, GICS implants as a strategy to minimize
the risk of DSWI should not be denied to patients at
higher risk of DSWI because DSWI exacts a high cost in
terms of high morbidity, mortality, and relative resource
consumption.7
Therefore we aimed to develop a scoring system for an
impartial assessment to guide decision making for the use
of GICS to prevent DSWI.METHODS
Study Population
The study was conducted in accordancewith the principles of the Decla-
ration of Helsinki. The local ethical committee approved the study, and the
requirement for individual patient consent was waived. We retrospectively
analyzed prospectively collected data from the PATS institutional surgical
database (Dendrite Clinical Systems, Ltd, Oxford, United Kingdom) from
April 2001 to January 2014. The PATS database captures detailed informa-
tion on a wide range of preoperative, intraoperative, and hospital postoper-
ative variables (including complications and mortality) for all patients
undergoing cardiac surgery in our institution. The data is collected and re-
ported in accordance with the Society for Cardiothoracic Surgery in Great
Britain & Ireland database criteria. The database is maintained by a team ofgery c November 2014
Abbreviations and Acronyms
BMI ¼ body mass index
CABG ¼ coronary artery bypass grafting
DSWI ¼ deep sternal wound infection
GICS ¼ gentamicin-impregnated collagen sponge
RCT ¼ randomized controlled trial
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prospective data collection as part of a continuous audit process. Data
collection is validated regularly.
Our analysis included adult patients undergoing cardiac surgery through
full sternotomy.
Pretreatment Variables and Study End Points
The effect of GICS implant on the incidence of DSWI was adjusted for
the following pretreatment variables: age, female gender, diabetes mellitus,
previous sternotomy, chronic obstructive pulmonary disease (defined as
long-term use of bronchodilators or steroids for lung disease or spirometry
showing airflow limitation; that is, a forced expiratory volume in 1 second
to forced vital capacity ratio<0.70 or less than the lower limit of normal
plus a forced expiratory volume in 1 second<80% of predicted), previous
stroke, peripheral vascular disease, left ventricular function, renal impair-
ment (defined as baseline serum creatinine>150 mmol/L), body mass in-
dex (BMI), nonelective indication and type of operation (isolated or
combined coronary artery bypass grafting [CABG], CABG vs other than
CABG procedure), including the use of bilateral internal mammary ar-
teries, and the harvesting technique used (skeletonized or pedicled).
The primary end points were the incidence of DSWI. As defined by the
Centers for Disease Control and Prevention, DSWI requires the presence of
1 of the following criteria: an organism isolated from culture of mediastinal
tissue or fluid; evidence of mediastinitis seen during operation; or presence
of either chest pain, sternal instability, or fever (>38C), and either purulent
drainage from the mediastinum, isolation of an organism present in a blood
culture, or culture of the mediastinal area.8 Superficial sternal wound infec-
tion, defined as an infection involving only skin or subcutaneous tissue at
the incision site, was excluded from this study.
GICS Implant Technique
Starting from 2007, GICS implant (Collatamp, EUSAPharma [Europe],
Oxford, United Kingdom)was used in patients deemed to be at high risk for
sternal wound complications according to the surgeon’s preference. Before
closure of the sternum and after placement of the sternal wires, a single
Collatamp sponge (20 3 5 3 0.5 cm; 1 cm2 containing 2.8 mg native
collagen fibrils of equine origin and also containing 2 mg gentamicin sul-
phate, equivalent to 1.10-1.43 mg gentamicin) was implanted without pre-
moistening. The sponge was placed transsternally between bone edges.
Sternal wires were then tightened. Collatamp is an approved Food and
Drug Administration prescription product.
Statistical Analysis
Multiple imputation using full Bayesian multiple imputation procedure
using the bootstrap was used to address missing data. Partial c2 Wald sta-
tistic from saturated main effects model was used to test the association of
each predictor with responses. Proportional odds ordinal logistic regression
models using ordinary unpenalized maximum likelihood estimation were
implemented to estimate individual linear predictors (ni) of DSWI. The
predicted probability was derived as 1/(1 þ exp(ni)). Fast backward elim-
ination on predictors was performed using Lawless and Singhal method,
which uses the fitted complete model and computes approximate Wald sta-
tistics by computing conditional (restricted) maximum likelihoodThe Journal of Thoracic and Carestimates assuming multivariate normality of estimates. Bootstrapping
validation of the regression models was performed using 200 samples of
the original data, with replacement, and the models were fitted using
training set. A testing set was finally used for validation. Somers’ Dxy
rank correlation coefficient was used as measure of discrimination. Dxy
corresponds to 2*(C  0.5) where C is the generalized receiver operating
characteristic area (concordance probability). Calibration curves were
then estimated using resampling. Density of linear predictor was assessed
as cause of model overfitting. The individual predicted risk for DSWI was
then derived and patients at higher risk for DSWI were defined as those
with a predicted DSWI higher than the 75th percentile of predicted
DSWI risk distribution. Predicted risk for DSWI was then plotted against
predictors for patients who received GICS implant and who did not to iden-
tify subgroups that are likely to benefit from GICS implant.
The effect of independent predictors was reported as a score in a nomo-
gram that can be used to manually obtain predicted individual risk of
DSWI. The nomogram has a reference line for reading scoring points
(default range 0-100). Once the reader manually totals the points, the pre-
dicted values can be read at the bottom.
R version 2.15.2 (R Foundation for Statistical Computing, Vienna,
Austria) and the rms package (R Foundation for Statistical Computing,
Vienna, Austria) were used for analysis.RESULTS
The final population consisted of 8750 adult patients un-
dergoing cardiac surgery through full sternotomy during the
study period. A total of 5275 patients underwent isolated
CABG and 973 patients (18.4%) received bilateral internal
mammary arteries. Skeletonized harvesting technique was
used in 421 patients.
A total of 329 patients (3.8%) received GICS implant.
Data regarding the incidence of DSWI was not available
for 106 patients and none of them received GICS implant.
Table 1 summarizes the distribution of baseline charac-
teristics, the number of missing values, and the proportion
of patients who developed DSWI postoperatively. The over-
all incidence of DSWI was 180 (2.0%). The relative effect
size of predictors on the incidence of DSWI is reported as
partial c2 Wald P value. Patients presenting with DSWI
were more likely to be women, obese, and diabetic taking
insulin. Isolated or combined CABG was more likely to
be associated with DSWI as well as the need for reexplora-
tion. The overall incidence of DSWI was lower among pa-
tients who received a GICS implant (0.6%) than patients
who did not (2.01%) (P ¼ .02). Fast backward elimination
on predictors selected the following variables as indepen-
dent risk factors for DSWI: female gender (c2 Wald, 5.7;
P<.0001), BMI (c2 Wald, 5.5; P<.0001), diabetic taking
insulin (c2 Wald, 3.1.8; P ¼ .001), need for reexploration
(c2 Wald, 10.1; P < .0001), and isolated or combined
CABG (c2 Wald, 3.1; P<.0001). Bilateral internal mam-
mary arteries significantly increased the risk of DSWI
(P ¼ .0001) but the internal mammary artery harvesting
technique did not show a significant effect on the inci-
dence of DSWI (P ¼ .3). GICS implant was retained
into the model as a protective factor (c2 Wald, 2.2;
P ¼ .02). The model showed a good discrimination powerdiovascular Surgery c Volume 148, Number 5 2391
TABLE 1. Patient characteristics and relative incidence of deep sternal wound infection (DSWI)*
Characteristic Category N DSWI
c2 statistic
P valuey
Age (y) 16-60 2310 0.014 .42
60-69 2305 0.026
69-75 1889 0.018
75-93 2140 0.023
Female gender No 6504 0.015 <.0001
Yes 2139 0.035
Missing 1 0.000
Body mass index 14.5-24.5 2143 0.011 <.0001
24.5-27.2 2135 0.016
27.2-30.4 2139 0.018
30.4-54.1 2138 0.036
Missing 89 0.011
Renal impairment No 8304 0.020 .45
Yes 335 0.020
Missing 5 0.000
Chronic obstructive pulmonary disease No 7686 0.020 .57
Yes 957 0.021
Missing 1 0.000
Previous stroke No 8511 0.020 .10
Yes 117 0.042
Missing 16 0.000
Diabetes mellitus No 6874 0.018 Ref
Oral therapy 1210 0.023 .61
Taking insulin 557 0.048 .0013
Missing 3 0.000
Peripheral vascular disease No 7881 0.020 .94
Yes 760 0.025
Missing 3 0.000
Left ventricular ejection fraction Good (50%) 6700 0.020 Ref
Moderate (>30% to<49%) 1458 0.021 .73
Poor (30%) 475 0.021 .75
Missing 11 0.000
Redo sternotomy No 8321 0.021 .66
Yes 322 0.015
Missing 1 0.000
Nonelective surgery No 6009 0.018 .17
Yes 2625 0.025
Missing 10 0.000
Surgery, including coronary artery bypass grafting No 2270 0.014 .003
Yes 6373 0.023
Missing 1 0.000
Gentamicin-impregnated collagen sponge No 8315 0.021 .02
Yes 329 0.006
Need for reexploration No 8027 0.016 <.0001
Yes 615 0.079
Missing 2 0.500
Overall 8750
No missing for DSWI 8644 .0208
Missing 106
Ref, Reference category; DSWI, deep sternal wound infection. *Missing data are reported. yThe P values were averaged over the 5 imputed model fits.
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M(C statistic ¼ 0.75). Bootstrapping validation confirmed a
good discriminative power of the model (Dxy training data-
set Dxy ¼ 0.49, testing dataset Dxy ¼ 0.49). Calibration
curve analysis showed a good predictive power of the model2392 The Journal of Thoracic and Cardiovascular Surfor value of predicted probability<0.10 (Figure 1). Beyond
this value, the model was overfit with an overestimation
of the actual risk and this was due to the small number of
patients (n ¼ 175; 2%) presenting a predicted risk>0.1.gery c November 2014
FIGURE 1. Bootstrap overfitting-corrected Loess nonparametric calibra-
tion curve for casewise deletion model for deep sternal wound infection
(DSWI).
FIGURE 2. Distribution of predicted risk for deep sternal wound infec-
tion.
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DSWI. The median DSWI predicted risk was 1% and the
75th percentile corresponded to 2%. This cut-off was cho-
sen to define patients at higher risk for DSWI. The graphic
representation of the effect on GICS implant of the pre-
dicted risk for DSWI according to BMI, gender, and need
for reexploration is reported in Figure 3. In patients who
did not require reexploration (Figure 3) the use of GICS
implant allowed to reclassify the following high-risk sub-
groups as low risk: male with diabetes and BMI> 30,
female without diabetes and BMI> 35, female with dia-
betes taking oral therapy and BMI> 30, and female with
diabetes taking insulin and BMI>25. In patients who did
require reexploration (Figure 3) the use of GICS implant
allowed us to reclassify the following high-risk subgroups
as low risk: male without diabetes or diabetes taking oral
therapy and BMI> 20, male with diabetes taking insulin
regardless of BMI, and female regardless of diabetes
status and BMI.
Finally a nomogram was derived with scores assigned for
the presence and magnitude of each predictor including the
use of GICS implant (Figure 4). The baseline score was
calculated using female gender (26 points), BMI (33, 44,
or 56 points for BMI of 25, 30, and 35, respectively), dia-
betes receiving insulin therapy (20 points), isolated or com-
bined CABG (19 points with and extra 15 points if BIMA
grafting was used), and need for reexploration (51 points).
A score 136 represented the cut-off score to identify pa-
tients at higher risk for DSWI (>2% predicted probability).
The use of GICS implant reduced the total score by 63
points (Figure 4 and Table E1). Therefore, in patients
with a baseline score ranging between 136 and 199 points,
the use of GICS alone was able to reclassify patients with aThe Journal of Thoracic and Carhigh risk profile into the lower risk category. Above this cut-
off level, GICS implant is expected to reduce the patient
profile risk, although these patients should be still consid-
ered to have a higher risk for DSWI.
No negative ototoxic or nephrotoxic aminoglycoside side
effects were recorded in patients who received GICS
implant.DISCUSSION
The main finding of our study was that a personalized in-
dividual assessment of DSWI risk was achievable for pa-
tients undergoing adult cardiac surgery through full
sternotomy. This scoring system is expected to guide the de-
cision making process for the use of GICS implants in pa-
tients at high risk for sternal would infection.
Surgical-site infection remains a major public health
problem despite the routine use of prophylactic systemic
antibiotics. In particular, DSWI after cardiac surgery sub-
stantially increases illness severity, hospital stay length,
mortality, and costs. It occurs in 0.5% to 4.4% of patients
after cardiac surgery overall and in up to 12% to 20% of
high-risk patients.2 Preventive measures include skin prep-
aration, prophylactic antibiotic therapy, control of the oper-
ating room environment, and improvements in surgical
techniques. Antibiotic prophylaxis has been a cornerstone
in surgical site infection prevention, and there is growing in-
terest in the local delivery of antibiotics.3 Local delivery can
potentially lead to a higher concentration of antibiotics
within the target site while minimizing the risk of systemic
toxicity.
Gentamicin has a broad spectrum of bactericidal activity
that includes staphylococci and gram-negative bacteria.
Local gentamicin administration is used to avoid diffusion
in tissues with disruption of the commensal flora anddiovascular Surgery c Volume 148, Number 5 2393
FIGURE 3. Graphic representation of the effect of gentamicin-impregnated collagen sponge (GICS) implant on the predicted risk for deep sternal wound
infection according to body mass index, gender, and need for reexploration. BMI, Body mass index.
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been proposed as 1 method of employing local delivery of
antibiotics.7 They are inexpensive, easy to use, and have
an established safety profile.9 The majority of the studies
published to date have demonstrated that prophylactic use
of GICS can significantly reduce the wound infection rate
following cardiac surgery (via sternotomy) compared with
standard treatment alone.3 Previous meta-analyses on
available randomized controlled trials (RCTs) suggested
that the application of GICS implants perioperatively may
be beneficial in preventing postoperative DSWI in
patients undergoing cardiac surgery.4,5 By pooling data
from the 4 trials10-13 (4672 patients), GICS use seemed to
significantly reduce DSWI rate (relative risk [RR], 0.62;
95% confidence interval [CI], 0.39-0.97; P ¼ .04).52394 The Journal of Thoracic and Cardiovascular SurSchimmer and colleagues10 conducted a double-blind
RCT on 800 consecutive patients undergoing cardiac sur-
gery with median sternotomy closure. Patients were ran-
domized into 2 groups; closure with GICS (maximum 143
mg gentamicin) or with simple collagen sponge retroster-
nally. The gentamicin group (2 of 354; 0.56% DSWI)/(7
of 354; 1.9% superficial sternal wound infection) versus
the placebo group (13 of 369; 3.5% DSWI)/(11 of 369;
2.9% superficial sternal wound infection) showed a RR
reduction of 83.9%/33.7%, respectively (P ¼ .013). Fri-
berg and colleagues11 in 2005 conducted a double-blind
RCT at 2 centers where 1950 consecutive patients undergo-
ing cardiac surgery were evaluated; sternotomy closurewith
GICS was compared with standard closure. Incidence of
SWI was noted during the postoperative stay and up to 2gery c November 2014
FIGURE 4. Nomogram for deep sternal wound infection (DSWI) risk prediction. (If bilateral internal mammary artery grafting is used, add 15 extra points).
CABG, Coronary artery bypass grafting; GICS, gentamicin-impregnated collagen sponge; BMI, body mass index.
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infection was 4.3% (42 of 983) in the GICS group, which
was lower than in the control group (9%; 87 of 967) (RR,
0.47; 95% CI, 0.33-0.68; P < .001). Two out of 4
RCTs11,12 failed to show a benefit from routine use of
GICS implant. Bennett-Guerrero and colleagues,12 in a
multicenter study, did not demonstrate any benefit of use
of GCCI over standard treatment. The authors suggested a
combination of factors to explain the lack of benefit seen
in the GCCI group, including differences in design and
ethnic differences between their study and the other positive
study. One important difference that the authors do not
highlight is the fact that the protocol for the Bennett-
Guerrero and colleagues study12 required that the implants
be wetted in saline before implantation. The effect of wet-
ting implants has been researched by Lovering and col-
leagues14 and they have shown that presoaking may
influence the gentamicin release profile of the GICS to
cause premature depletion of the active compound in addi-
tion to that lost during the presoaking period. The manufac-
turer’s recommendation is that GICS should be used dry
before implantation. Friberg and colleagues15 point out
that in contrast to the other published studies a large propor-
tion of the sternal wound infections in the Bennett-Guerrero
and colleagues study12 were caused by gram-negative rods
that are not normally found on the skin of the chest (and
should not be present in the air in operating rooms) and
this might suggest that contamination may have occurred
later in the postoperative phase. Finally Shimmer and col-
leagues10 point out that a multicenter study is meant to be
unsuitable for addressing the question being investigated.
The aim was to evaluate the efficacy of a single procedureThe Journal of Thoracic and Car(ie, the use of a gentamicin-collage sponge) with respect
to a complication with a low incidence and multifactorial
genesis. This requires keeping all potential influencing fac-
tors as constant as possible. Otherwise, the positive effect of
a procedure could be swamped by the overall influence of a
wide range of factors. Furthermore, it is difficult to assess
the effect of the sponge in isolation because there was
apparently little standardization of practice in relation to
stabilization of the sternum in individual studies, let alone
across studies. It is well established that failure to achieve
stabilization of the sternum is associated with an increased
incidence of postoperative infection. Eklund and col-
leagues13 also showed no additional benefit of GCCI in
reducing wound infection rate following cardiac surgery.
The authors themselves concluded that the study population
might have been too small to draw conclusions.
Despite the fact that GICS implant has been shown to
reduce the incidence of DSWI, the effectiveness of the
routine retrosternal placement of a GICS implant before su-
ture closure is currently a matter of some controversy.6
Despite the routine use of GICS to reduce the incidence
of DSWI, surgeons are reluctant to implant it in all patients
because nearly 98% of patients are not expected to develop
sternal infection regardless of its use. As a consequence, the
indiscriminate application of GICS implant might not be
cost-effective. It has been suggested that the use of GICS
implant should be used only in high-risk patients.7 Of
note, 2 out of 4 RCTs we reviewed included participants
defined a priori as high risk: Bennett-Guerrerro and col-
leagues12 only included high-risk patients (defined as hav-
ing diabetes and/or a BMI higher than 30), whereas
Friberg and colleagues11 included a high-risk subgroupdiovascular Surgery c Volume 148, Number 5 2395
Perioperative Management Benedetto and Raja
P
Mdefined as having diabetes and/or a BMI higher than 25. The
2 studies with participants who were considered high risk
also reported the incidence of DSWI. Creanor and col-
leagues4 demonstrated a statistically significant difference
between the intervention and control groups in the inci-
dence of DSWI pooling data from high-risk patients (OR,
0.62; 95% CI, 0.39-0.98).
Our scoring system provides an impartial assessment for
decision making to establish if the use of GICS implant is
effective in reducing the risk of DSWI in individual pa-
tients. As previously reported2,16,17 we found female
gender, increased BMI, having diabetes and taking
insulin, reexploration for bleeding, and history of CABG
as an isolated or combined procedure as independent risk
factors for DSWI. The use of GICS implants showed a
protective effect on the incidence of DSWI. According to
our scoring system, we suggest that the use of GCSI
implants should be recommended in patients with a
predicted risk>2% (75th percentile) corresponding to an
overall score of 136 or higher. In patients with a baseline
score ranging between 136 and 199 points, the use of
GICS alone is expected to reclassify patients with a high
risk profile into the lower risk category. Above this cut-off
level, GICS implant is expected to reduce a patient’s risk
profile, although these patients should be still considered
at higher risk for DSWI and additional strategies should
be considered, such as prolonged antibiotic prophylaxis.
Our results must be interpreted taking into account
several limitations. Like any investigation of data on file,
our study’s findings are dependent on the quality of the data-
base, which is open to a variety of measurement biases.
Despite the fact that this database is validated regularly, it
is not possible to guarantee that no information was left
out of the patient charts and thus, our database. Further-
more, we cannot exclude that because this was a single
site study at a tertiary medical center with internal valida-
tion, there is a question of applicability to the general pop-
ulation. This could be addressed by external validation in a
nationwide patient population. In addition, it is important to
emphasize that the score, by definition, can only explain a
fraction of variables that affect the risk of DSWI. Intraoper-
ative management as well as elements of postoperative care
can affect the incidence of DSWI.CONCLUSIONS
Decision making for the use of GICS implant after ster-
notomy has traditionally been an area free from a compel-
ling evidence base. Our score provides a valuable tool in
the decision-making process for clinicians to establish if2396 The Journal of Thoracic and Cardiovascular SurGICS is expected to reduce the risk of DSWI. To the best
of our knowledge, this is the first study that developed a
nomogram to assess individual risk of DSWI in patients un-
dergoing cardiac surgery. Such an instrument might help to
more clearly and objectively define the often uncertain line
that separates patients at high risk for DSWI and who might
benefit from additional prophylactic strategies such as the
use of GICS implants. Further validation studies are needed
to confirm these findings.
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TABLE E1. Scoring system and predicted risk of deep sternal wound
infection (DSWI) according to total points
Predictor Points Total points
Predicted
risk
Female gender 26
Body mass index 51 0.10%
15 11 116 1.00%
20 22 136 2.00%
25 33 147 3.00%
30 44 156 4.00%
35 56 162 5.00%
40 67 168 6.00%
45 78 172 7.00%
50 89 177 8.00%
55 100 180 9.00%
Diabetes mellitus taking insulin 20 183 10.00%
Isolated or combined coronary
artery bypass grafting
19 196 15.00%
Reexploration 51 206 20.00%
Gentamicin-impregnated collagen
sponge implant
63 214 25.00%
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